Currently, IL-17 inhibitors are primarily used in treating immune-related diseases such as psoriasis and AS (Yin et al., 2020; Thomas et al., 2024); however, they may also have significant therapeutic potential in other immune-mediated diseases. This evidence concerns the gene IL17A and psoriasis.